Cavadis has an ambitious and business minded team. We have a strong background in cardiovascular biomarker discovery, medical and systems biology, diagnostics development and the business acumen to turn basic science into clinical products.
Chief Executive Officer (CEO) - Before joining Cavadis, Heico Breek held senior management positions in both Europe and the United States at
Aventis Pharma as Vice-President Global Marketing for Aventis’ Arthritis and Bone Group. In 2001-2003 he was General Manager of Aventis AB in Sweden and in 2004-2008 he was Chief Commercial Officer of
Tigenix NV, a Belgian biomedical company active in the field of Regenerative Medicine. He holds a Medical Degree from the VU University Amsterdam (Vrije Universiteit) and an executive MBA.
Read more
Chief Scientific Officer (CSO) - Gerard Pasterkamp, MD, PhD, is a Professor and head of the
Experimental Cardiology Laboratory at the
UMCU. In addition to being a medical doctor, he has a degree in clinical epidemiology. He serves on many national and international academic boards and institutes. Gerard has a strong scientific
track record in the field of arterial remodelling. In 2002 he envisioned the strategic power of a large scale atherosclerotic biobank (the
Athero-Express) containing plaque and plasma samples and associated long-term follow up data.
Read more
Project Manager - Dr. Herfita Agustiandari received her Bachelor of Science in Biotechnology and Biomedical Science from St. Cloud State University, USA. She worked for several years in the US biotech industry (
Life Technologies Co., former
Invitrogen Inc., and
Zymed Laboratories Inc.) and in Indonesia
Kalbe Farma. She is responsible for the management of the diagnostic assay being developed in collaboration with our academic and industrial partners. She received her PhD from the University of Groningen, the Netherlands.
Read more
Related items
Our missionCavadis is a Dutch biomedical company active in the field of cardiovascular risk assessment. The company's mission is to identify patients at risk of developing heart attacks and strokes. Our ultimate goal is to develop clinically meaningful risk stratification tools that will help personalize treatment and achieve better patient outcomes.
read more